… methods on the efficacy of erlotinib treatment. For the Group-II patients, we assessed their
EGFR mutation status by DS and calculated the number of EGFR mutations that would not be …

… However, after January 2011, EGFR mutation testing was … EGFR mutated patients in our
study (1.5%) received erlotinib as first-line treatment. All patients were treated with erlotinib until …

… their efficacy in patients with rare EGFR mutations. While gefitinib, erlotinib, and afatinib have
proven efficacy in patients with the two major mutations in the EGFR gene (ie, the classical …

… Our study confirms the previous efficacy data of afatinib for NSCLC harboring uncommon
EGFR mutations other than T790M. Compared with gefitinib and erlotinib, afatinib treatment …

… by EGFR mutation status. This meta-analysis demonstrated that EGFR mutations predict
response to EGFR … , NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or …

… EGFR mutation screening, it also examined the influence of EGFR mutations on the efficacy
of … can be the most important predictive factor for efficacy of TK inhibitors, so we analyzed …

… Our study first found that EGFR mutations are common in … that EGFR mutations can predict
gemcitabine plus erlotinib … detected between EGFR mutations and the efficacy of erlotinib in …

… efficacy of gefitinib in patients with uncommon mutations, we conducted a post-hoc analysis
of the NEJ002, which compared gefitinib … advanced NSCLC with activating EGFR mutations. …

… In the present study, we compared the efficacy of erlotinib, a first-generation EGFR-TKI,
with … that erlotinib as neoadjuvant therapy was well-tolerated and beneficial in EGFR-mutant …

… the efficacy of erlotinib in this … the efficacy of erlotinib in a series of patients with brain
metastases from NSCLC and its association with the presence of activating mutations in the EGFR …